“Thermo Fisher has an exceptional track record of success in the manufacture of clinical and commercial cell and gene therapies and a well-established global network to meet the needs of our customers,” said Tim Kelly, Chief Executive Officer of RoosterBio. “Biopharmaceutical companies striving to develop engineered cell and exosome therapies require proven, flexible technologies paired with reliable and scalable manufacturing capabilities. Through this collaboration, we will deliver that comprehensive solution to our customers, and I am delighted to work with Thermo Fisher to translate our MSC and exosome technologies into advanced therapy products for patients around the world.”
“Our collaboration with RoosterBio reflects our shared commitment to helping life-changing therapies reach patients in need, in the safest, fastest and most effective way possible,” said Ben Castro, Vice President and General Manager, Large Molecule, pharma services, Thermo Fisher. “We’re excited to work with the team to expand our Contract Development Manufacturing Organization (CDMO) services and support our biotechnology partners through the research and optimization, process development and manufacturing of critical treatments.”
Consistent with global best practices, RoosterBio prioritizes the safety and efficacy of its products through robust bioethical standards, including hMSCs being sourced under stringent guidelines, manufactured using highly standardized processes, and supported by first-in-class characterization.
About RoosterBio
RoosterBio accelerates human mesenchymal stem/stromal cell (hMSC) and extracellular vesicle (EV) product and process development to fuel the rapid implementation of scalable advanced therapies. Our high-quality hMSCs, bioprocess media, genetic engineering tools, and EV production solutions are paired with expert bioprocessing knowledge to progress therapeutic developers from concept to first-in-human testing and commercial manufacturing at reduced cost and increased productivity. With optimized, scalable processes, Type II Master Files, and cGMP products, we have enabled therapeutic programs to traverse their path to clinical translation in under one year. RoosterBio is driven by clients’ success and creating a world where safe and effective regenerative medicines are rapidly developed and widely available on a global scale. For more information, please visit www.roosterbio.com
Media Contact
Kim Hastings, RoosterBio, inc., 1 301.200.5366, [email protected], www.roosterbio.com
SOURCE RoosterBio, inc.
